WuXi PharmaTech Inc., a pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced it has reached an agreement with Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica, N.V. (J&JPRD) to expand its pharmaceutical R&D services collaboration. The new broad agreement aims to deepen the already long-standing relationship between J&JPRD and WuXi PharmaTech. WuXi, already a preferred research services provider to J&JPRD for discovery chemistry, will now provide integrated research services in the area of discovery chemistry, discovery biology, chemical and analytical development services, formulation, and preclinical and bio-analytical services, to enhance drug discovery and shorten development timelines. Commenting on the agreement, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech, said, “We are very pleased to expand our partnership with J&JPRD. This agreement leverages WuXi’s strong R&D capabilities from early stage discovery to commercial production to deliver reliable, high quality and cost-efficient services to J&JPRD. Our partnership demonstrates the strength of our innovation driven and fully integrated R&D service platform.”
